Anavex Life Science

Q3 FY2026 EarningsAVXL.US Q3 FY26 beat consensus on bottom-line metrics despite reporting zero revenue, consistent with its clinical-stage status. GAAP Net Loss was $5.3M vs. $7.6M expected, and EPS was -$0.06 vs. -$0.08 expected. The variance was primarily driven by a sharp reduction in R&D expenses ($4.2M vs. $9.9M YoY) following the completion of the ANAVEX 3-71 schizophrenia trial and de-prioritization of non-core assets. While liquidity remains stable with $127.4M in cash, the company faces significant governance headwinds following the termination of its former CEO for Cause and ongoing Nasdaq non-compliance regarding late filings.